Chronic myelogenous leukemia

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 5, 2007, Pages 474-496

  O'Brien, Susan ^a   Berman, Ellin ^b   Bhalla, Kapil ^c   Copelan, Edward A ^d   Devetten, Marcel P ^e   Emanuel, Peter D ^f   Erba, Harry P ^g   Greenberg, Peter L ^h   Moore, Joseph O ⁱ   Przepiorka, Donna ^j   Radich, Jerald P ^k   Schilder, Russell J ^l   Shami, Paul ^m   Smith, B Douglas ⁿ   Snyder, David S ^o   Soiffer, Robert J ^p   Tallman, Martin S ^q   Talpaz, Moshe ^g   Wetzler, Meir ^r  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e NEBRASKA MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^h STANFORD CANCER INSTITUTE   (United States)

ⁱ DUKE CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^k SEATTLE CANCER CARE ALLIANCE   (United States)

^l FOX CHASE CANCER CENTER   (United States)

^m UNIVERSITY OF UTAH   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

^o City of Hope Cancer Center   (United States)

^p MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

Chronic myelogenous leukemia; Desatinib; Imatinib; Karyotyping; NCCN clinical practice guidelines; Polymerase chain reaction; Transplantation

Indexed keywords

ANAGRELIDE; APREPITANT; CALCIUM; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; DASATINIB; DEXAMETHASONE; DIURETIC AGENT; ERYTHROMYCIN; ERYTHROPOIETIN; GASTROINTESTINAL AGENT; GROWTH FACTOR; HYDROXYUREA; HYPERICUM PERFORATUM EXTRACT; IMATINIB; INTERFERON; ITRACONAZOLE; KETOCONAZOLE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PREDNISONE; RIFABUTIN; RIFAMPICIN; SIMVASTATIN; STEROID; UNINDEXED DRUG; WARFARIN;

ANEMIA; APHERESIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BLAST CELL CRISIS; BONE MARROW BIOPSY; CANCER REGRESSION; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY DYSFUNCTION; LEUKOCYTOSIS; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG TOXICITY; MEMORY; MENTAL CONCENTRATION; MUSCLE CRAMP; NEUTROPENIA; PARKINSONISM; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRACTICE GUIDELINE; RASH; RESPIRATORY DISTRESS; REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; THROMBOCYTOPENIA; THROMBOCYTOSIS;

EID: 34249288276     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0043     Document Type: Review

References (65)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340: 1330-1340.
3. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.
4. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995;85:2632-2638.
5. Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 2001;98: 1701-1707.
6. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432.
7. Iacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006;12:3037-3042.
8. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-3432.
9. Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate treated patients with CML. Blood 2006;107:4250-4256.
10. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
11. Guo JQ, Wang JY, Arlinghaus RB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Res 1991;51:3048-3051.
12. Muhlmann J, Thaler J, Hilbe W, et al. Fluorescent in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer 1998;21:90-100.
13. Cortes JE, Talpaz M, Beran M, et al. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer 1995;75:464-470.
14. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
15. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
16. Druker BJ, Guilhot S, O'Brien S, et al. Long term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia in chronic phase: the 5-year update from the IRIS study [abstract]. J Clin Oncol 2006;24(suppl 1):338s. Abstract 6506.
17. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-2878.
18. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-968.
19. Efficacy of 400 mg versus 800 mg imatinib in chronic myeloid leukemia in chronic phase patients. Clinical Trials.gov. Available at http://clinicaltrails. gov, identifier: NCT00124748. Accessed March 18, 2007.
20. Imatinib mesylate or dasatinib in treating patients with chronic phase chronic myelogenouse leukemia. Clinical Trials.gov. Available at http://clinicaltrails.gov, identifier: NCT00070499. Accessed March 18, 2007.
21. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758-1766.
22. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cells lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: diverse mechanisms of resistance. Blood 2000;96:1070-1079.
23. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498-3505.
24. Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-2097.
25. Cortes, J, O'Brien S, Quintas A, et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 2004;100:2396-2402.
26. Kantarjian H, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (ST1571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003;9:160-166.
27. Feldman E, Najfeld V, Schuster M, et al. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003;31:702-777.
28. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905-1911.
29. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004;18:1340-1346.
30. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib resistant Philadelphia chromosome-positive leukemias. N Eng J Med 2006;354:2531-2541.
31. Sprycel® dasatinib [Package Insert]. Princeton, NJ: Bristol-Myers Squibb.
32. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendarions from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820.
33. Kantarjian HM, Deisserorh A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703.
34. Savage DG, Szydlo RM, Chase A, et al. Bone marrow Transplantation for chronic myeloid leukemia: the effects of differing criteria for defining chronic phase on probabiliries of survival and relapse. Br J Haematol 1997;99:30-35.
35. Sokal JE, Baccarani M, Russo D, et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49-61.
36. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon (France): IARC Press; 2001.
37. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater like-lihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100-4109.
38. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistant and mutation in the ATP phosphate-binding loop are associated with a poor prognosis. Blood 2003;102:276-283.
39. Branford S, Rudzki Z, Parkinson I, et al. Real time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-2932.
40. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resisrance mutations in BCR-ABL. Curr Opin Hematol 2003;11:35-43.
41. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128-2137.
42. Khorashad JS, Anand M, Marin D, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006;20:658-663.
43. Davies SM, DeFor TE, McGlave PB et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339-346.
44. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-3400.
45. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
46. Giralt S, Thall P, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-637.
47. Or R, Shapira M, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003;101:441-445.
48. Crawley C, Szyldo R, Lalancette M, et al. Outcomes of reduced intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969-2976.
49. Clift RA, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996;17(suppl 3):S1-3.
50. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17(suppl3):S5-6.
51. Goldman J, Szydlo R, Horowitz MM, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993;82:2235-2238.
52. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995;85:2981-2990.
53. Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998;92:394-401.
54. Zander A, Zabelina T, Renges H, et al. Pretreatment with Glivec increases transplant-related mortality after allogeneic transplant [abstract]. Abstract 1708. 2003 Annual Meeting, American Society of Hematology, December 6-9, San Diego, CA.
55. Shimoni A, Kroger N, Zander AR, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003;17: 290-297.
56. Anderlini P, Sheth S, Hicks K, et al. Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 2004;10:883-884.
57. Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006;91:452-459.
58. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplant for chronic myeloid leukemia. Blood 2007;109:1782-1789.
59. Mackinnon S, Barnett L, Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996;17:643-647.
60. Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001;97:1560-1565.
61. Kolb HJ, Schattenberg A, Goldman JM, et al. Graff-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-2050.
62. Higano CS, Chielens D, Raskind W, et al. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 1997;90:2549-2554.
63. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002;100:1590-1595.
64. Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003;17:1707-1712.
65. Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005;23:7583-7593.